Tasly Pharmaceutical Posts Higher Profit in H1; Shares Rise 7%
MT Newswires Live
Aug 18
Tasly Pharmaceutical Group (SHA:600535), a unit of China Resources Pharmaceutical (HKG:3320), reported a 17% rise in net profit attributable to shareholders to 774.7 million yuan for the six months ended June 30, compared with 662.3 million yuan a year earlier, according to an Aug. 15 Hong Kong bourse filing.
Shares of Tasly rose nearly 7% in late-morning trade Monday.
Earnings per share came in at 0.52 yuan from 0.44 yuan a year earlier.
Revenue slipped nearly 2% to 4.29 billion yuan, compared with 4.37 billion yuan a year ago.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.